# Pizarra — PT-pseudo_47d8b39fd07f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.52 +/- 0.22   (95% CI 0.12-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.1 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=1.0, psa=21.0, age=60.0, psad=0.19, dre_ord=0.0, vol=112.15, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS 3, PSA 21.0, PSA density 0.19, etc.) and could not account for the clinical context, such as the patient's history of rising PSA trajectory (23.5 to 21.0 ng/mL) or the specific clinical concern mentioned in the chief complaint (rising trajectory combined with intermediate findings).
The prior cannot weigh the clinical significance of the rising PSA velocity (5.99 ng/mL/yr) or the patient's symptoms (IPSS 17), which are crucial for risk stratification beyond the static imaging metrics.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 52% probability, which falls into the 'discuss' tier, meaning the classifier genuinely cannot distinguish between biopsy and no biopsy based on the limited input. This is wrong because the EXPERT-PROTOCOL explicitly states to DEFER BIOPSY for a PI-RADS 3 picture that has not changed, which the prior failed to incorporate.
The prior ignores the guideline criterion that mandates deferral unless the MRI findings have changed, which is a critical internal contradiction given the patient's history of a prior negative biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior negative biopsy
laboratory panel - full panel
family-history anamnesis - for risk factor assessment

GUIDELINE ANCHOR
The guideline constrains the decision by stating that a repeat biopsy is not warranted for a PI-RADS 3 picture that has not changed, recommending active surveillance as standard of care for low-risk disease.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
mpMRI Prostate | LUMC | 15 Jan 2025: PI-RADS 3 lesion in the right mid-gland peripheral zone. Lesion size is 12 mm. No extraprostatic extension.

get_psa_trend
psa_trend: [{"date": "Mar 2022", "val": 2.5}, {"date": "Feb 2023", "val": 6.9}, {"date": "Feb 2024", "val": 19.3}, {"date": "Jan 2025", "val": 21.0}]

get_previous_notes
previous_notes: [{"date": "01 Aug 2023", "author": "Dr. R. van den Berg (GP)", "text": "Routine follow-up captured PSA at 11.5 ng/mL. Moderate lower urinary tract symptoms are present, though haematuria and bone pain are denied. Urology referral for further workup and multiparametric MRI was arranged with patient consent."}, {"date": "27 May 2024", "author": "Dr. R. van den Berg (GP)", "text": "Repeat testing shows PSA elevation to 23.5 ng/mL. LUMC imaging identified a PI-RADS 3 lesion, while the earlier systematic biopsy yielded Negative results. Urology re-evaluation was scheduled to review the imaging and laboratory data."}]

get_lab_results
laboratory_results: [{"name": "PSA", "val": "21.0 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.22 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "09 Dec 2024", "flag": "L"}]

NOT RETRIEVED
get_family_history
Family history anamnesis was not retrieved because it is not required for this decision based on the retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Rising PSA trajectory: 23.5 ng/mL (Feb 2024) to 21.0 ng/mL (Jan 2025), with a velocity of 5.99 ng/mL/yr.
- PI-RADS 3 lesion: The mpMRI shows a PI-RADS 3 lesion in the right mid-gland peripheral zone.

AGAINST sampling this patient now:
- Prior negative biopsy: Prior biopsy result was Negative.
- PI-RADS score: PI-RADS 3 is below the threshold (4-5) for mandatory re-biopsy according to the protocol.

WHERE THIS LEANS
The evidence is divided: the rising PSA trajectory and the PI-RADS 3 finding argue for further investigation, but the prior negative biopsy and the PI-RADS 3 score below the threshold argue against immediate re-biopsy, aligning with the EXPERT-PROTOCOL's deferral criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

I defer biopsy because the EXPERT-PROTOCOL criterion mandates deferral for a PI-RADS 3 finding that has not changed, which the retrieved evidence confirms. Although the PSA trajectory was rising (23.5 to 21.0 ng/mL), the PI-RADS 3 score is below the threshold for mandatory re-biopsy. The prior negative biopsy is a strong factor against further sampling without new imaging findings. The statistical prior suggested biopsy, but the guideline and retrieved data converge on deferral.

Variables that carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
